Treatment - Cancer Currents Blog
Cancer treatment related news, with context from leading experts. Includes articles on new therapies, treatment side effects, and important trends in treatment-related research.
-
New clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes.
-
Researchers have identified proteins that may play a central role in transforming T cells from powerful destroyers to depleted bystanders that can no longer harm cancer cells. The findings could lead to strategies for boosting cancer immunotherapies.
-
Some women with endometrial cancer may be able to receive less intensive treatment, chemotherapy and no radiation, without increasing their risk of the disease recurring within 5 years, according to the results of a randomized clinical trial.
-
Olaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
-
In two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with the androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies.
-
The Food and Drug Administration has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
The drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from a clinical trial.
-
FDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer.
-
New findings from a clinical trial of the drug tagraxofusp confirm its efficacy against the rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN).
-
The expanding use of cancer immunotherapy has revealed a variety of side effects associated with this treatment approach. Researchers are now trying to better understand how and why these side effects occur and develop strategies for better managing them.